Stockwinners Market Radar for April 05, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:43 EDT SSR Mining updates ongoing recovery efforts at the Copler mine - "SSR Mining provides an update on the ongoing recovery efforts at the Copler mine in Turkiye. Since the February 13 incident, the priority at Copler has been the recovery of our nine missing colleagues. In the evening of Friday, April 5, the body of one of the missing personnel was recovered from the Manganese Pit. The family of the deceased has been notified, along with the relevant government authorities. Our thoughts continue to be with all of the impacted families. The search for our missing colleagues continues, with over 4 million tonnes of displaced material removed to date from the Sabrl Valley, Manganese Pit and heap leach pad."

18:19 EDT Bausch Health files patent lawsuit against Amneal Pharmaceuticals - Bausch Health Companies (BHC) along with its gastroenterology business, Salix Pharmaceuticals, announced that it filed a lawsuit in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals (AMRX) of New York, Amneal EU, Limited, Amneal Pharmaceuticals, Amneal Pharmaceuticals Private Limited, and Amneal Pharmaceuticals. This lawsuit follows receipt of a Notice of Paragraph IV Certification stating that Amneal submitted an Abbreviated New Drug Application to the U.S. FDA seeking approval to market a generic version of XIFAXAN 550 mg tablets. Amneal asserts that certain patents listed in the FDA's Orange Book for XIFAXAN are unenforceable, invalid, and/or not infringed by Amneal's ANDA product. This action formally initiates the litigation process under the Hatch-Waxman Act and triggers a 30-month stay of any potential FDA approval for Amneal's ANDA.

17:07 EDT L3Harris awarded $155.25M government contract - L3Harris Global Communications Inc., Rochester, New York, was awarded a $155,250,000 firm-fixed-price contract for mobile and secure communications services. Bids were solicited via the internet with two received. Work locations and funding will be determined with each order, with an estimated completion date of April 5, 2028. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity.

17:06 EDT Werewolf Therapeutics to present data from studies of WTX-518, WTX-712 at AACR - Werewolf Therapeutics is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research Annual Meeting, taking place April 5-10 in San Diego, California."We are excited to share that both WTX-518 and WTX-712 demonstrate powerful immunotherapeutic effects in preclinical models," said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. "WTX-518 exhibits remarkable tumor-selective activation, resistance to IL-18BP and robust immune activation, overcoming key hurdles in the use of this promising cytokine in cancer therapy. WTX-712 acts through a unique mechanism that robustly activates tumor-specific T lymphocytes with an expanded therapeutic window through its selective release of wild-type IL-21 in the TME. These data collectively highlight the innovative strategies we are pursuing to further expand the repertoire of unique immune stimulating cytokine mechanisms in the fight against cancer." Results highlighting WTX-518 findings are summarized in a poster titled, "Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models" (Abstract #4074). Key takeaways reveal that WTX-518: is inducible, and its in vitro activity is not impeded by IL-18BP; selectively delivers active binding protein resistant IL-18 to the tumor microenvironment; and promotes increased influx and activation of NK cells and polyfunctional CD8 T cells in the TME, and demonstrates complete tumor regression in the MC38 mouse tumor model. The WTX-712 data are summarized in a poster titled, "WTX-712, a conditionally active IL-21 INDUKINE molecule, induces a strong anti-tumor phenotype through a differentiated mechanism" (Abstract #4078). Key takeaways reveal that: WTX-712 demonstrates inducibility and antitumor activity with regressions in the MC38 mouse tumor model; IL-21 HLE has superior anti-tumor efficacy compared to IL-2 HLE therapy in mouse tumor models that are highly resistant to anti-PD-1/PD-L1 treatment, in part due to the activation of type-I IFN pathways; and IL-21 HLE promotes sustained expansion and activation of tumor infiltrating CD8 T cells with increased polyfunctionality and induces expression of cytotoxic effector molecules (Granzyme A, Granzyme B, and perforin). Werewolf plans to develop WTX-518 and WTX-712 as potential immunotherapies in refractory and/or immunologically unresponsive tumors.

17:01 EDT Surf Air Mobility receives continued listing standard notice from NYSE - Surf Air Mobility announced that on April 2, it received notice from the New York Stock Exchange that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of Surf Air's Common Stock was less than $1.00 over a consecutive 30 trading-day period. The NYSE notice has no immediate impact on the listing of Surf Air's Common Stock, and the Common Stock will continue to be listed and trade on the NYSE, subject to Surf Air's compliance with other NYSE continued listing standards.

16:53 EDT Tesla CEO Musk says Tesla Robotaxi to be unveiled August 8 - In a post on X, formerly Twitter, Tesla CEO Elon Musk said that the Tesla Robotaxi will be unveiled on August 8. Reference Link

16:31 EDT Associated Capital reports preliminary Q1 book value per share of $42.67-$42.87 - Associated Capital Group announced a preliminary range for its first quarter book value of $42.67 to $42.87 per share. This compares to $42.11 per share at December 31, 2023 and $41.30 per share at March 31, 2023.

16:30 EDT Eli Lilly sees Q1 pre-tax IPR&D charges of roughly $111M - Eli Lilly said it currently expects that its reported financial results calculated in accordance with U.S. generally accepted accounting principles and its non-GAAP financial results for the first quarter of 2024 will include acquired IPR&D charges of approximately $111M on a pre-tax basis, representing a charge of approximately 10c to both GAAP and non-GAAP earnings per share. Lilly's results for the quarter ended March 31, 2024, have not been finalized and are subject to Lilly's financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. As previously disclosed, while acquired IPR&D charges may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, Lilly does not forecast acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period.

16:10 EDT Vital Farms COO to transition to advisory role - In a regulatory filing, Vital Farms disclosed that on April 3, the company entered into a transition agreement with Jason Dale, the company's COO and principal operating officer, pursuant to which Dale will transition into a non-employee advisory role with the company. The company is engaged in a search for a Chief Supply Chain Officer to assume certain of Dale's responsibilities. Pursuant to the COO Transition Agreement, Dale will serve as COO and principal operating officer until the earlier to occur of: (i) the start date of the company's Chief Supply Chain Officer or (ii) August 31. On August 31, Dale will transition to a non-employee advisory role through December 31 to ensure a smooth leadership transition

16:05 EDT Radcom CEO Shemesh to step down, Itman named interim CEO - Radcom announced that the Board has appointed Mr. Hilik Itman as interim CEO, effective April 7, 2024. Hilik, who has served as the Company's Chief Operating Officer since 2020, brings 27 years of invaluable experience with Radcom, having held various key roles in R&D and serving as Vice President of Research and Development since 2014. Mr. Guy Shemesh, who assumed the CEO role in mid-February, is stepping down, effective April 7, 2024, due to personal reasons. The board has initiated a thorough search process for a permanent CEO to lead the company into the next phase of its growth and transformation journey.

16:00 EDT Vitru Ltd trading resumes

15:48 EDT Adlai Nortye Ltd (ADR) trading resumes

15:35 EDT Enphase Energy disclosed resignation of Chief Commercial Officer - Enphase Energy disclosed earlier today that David Ranhoff, Chief Commercial Officer, notified the company of his intention to step down, effective as of June 30. Ranhoff will transition from his current position to a part-time role as commercial advisor, effective July 1. "Mr. Ranhoff is stepping down for personal reasons and there are no disagreements between Mr. Ranhoff and the Company on any matters relating to the Company's operations, policies or practices," Enphase added.

15:31 EDT Adlai Nortye Ltd (ADR) trading halted, volatility trading pause

15:13 EDT CRH acquires BoDean Company Inc. and Northgate Ready Mix, no terms - CRH announced the acquisition of BoDean Company Inc. and Northgate Ready Mix in Santa Rosa, CA. These acquisitions represent the first entry by CRH's Materials Solutions business into the state of California and enhance CRH's ability to provide integrated solutions to customers in the attractive Northern California market. Both companies complement CRH's Materials Solutions business in the Western U.S. and add two aggregates quarries, two ready mixed concrete plants, one asphalt plant and one recycle plant to its operations. BoDean and Northgate have proven track records for supplying customers with quality materials and are also known for innovation and sustainability.

15:08 EDT Sapiens jumps 7% to $33.32 after Reuters says exploring sale

14:57 EDT Sapiens trading halted, volatility trading pause

14:42 EDT Arrowroot Acquisition Corp trading halted, volatility trading pause

13:02 EDT Baker Hughes reports U.S. rig count down 1 to 620 rigs - Baker Hughes reports that the U.S. rig count is down 1 from last week to 620 with oil rigs up 2 to 508, gas rigs down 2 to 110 and miscellaneous rigs down 1 to 2. The U.S. Rig Count is down 131 rigs from last year's count of 751 with oil rigs down 82, gas rigs down 48 and miscellaneous down 1. The U.S. Offshore Rig Count is unchanged at 20, up 3 year-over-year. The Canada Rig Count is down 15 from last week to 136, with oil rigs down 10 to 65, and gas rigs down 5 to 71. The Canada Rig Count is up 9 from last year's count of 127, with oil rigs up 13, and gas rigs down 4.

13:01 EDT Capital Bancorp appoints Anguel Lindarev as EVP, CIO, effective immediately - Capital Bank announced the appointment of Anguel Lindarev as Executive Vice President and Chief Information Officer, effective immediately. "Anguel's impressive track record in leading technology operations and his forward-thinking approach to digital transformation make him the ideal leader to drive our IT strategy," said Ed Barry, CEO of Capital Bank. Prior to joining Capital Bank, Lindarev served as Executive Vice President, Chief Information Officer of American National Bank.

12:47 EDT Cazoo Group trading resumes

12:37 EDT Edible Garden AG Inc trading resumes

12:03 EDT GE Aerospace declares 28c per share quarterly dividend - GE Aerospace declared a 28c per share dividend on the outstanding common stock of the company. The dividend is payable April 25, to shareholders of record at the close of business on April 15. The ex-dividend date is April 12. GE's dividend before the spinoff was 8c per share.

12:00 EDT Mytheresa falls -8.4% - Mytheresa is down -8.4%, or -31c to $3.36.

12:00 EDT Coeur Mining rises 9.8% - Coeur Mining is up 9.8%, or 42c to $4.76.

12:00 EDT Transportadora de Gas del Sur SA rises 16.4% - Transportadora de Gas del Sur SA is up 16.4%, or $2.75 to $19.47.

11:39 EDT Musk says "Reuters is lying' following report of ending low cost car

11:11 EDT Paramount sinks 5% after CNBC report details Skydance offer - The offer would keep Paramount public and be dilutive to shareholders, according to CNBC. Paramount shares are down 5% to $11.81 in morning trading.

11:04 EDT Theratechnologies appoints Elina Tea to board of directors - Theratechnologies announced the appointment of Elina Tea, CFO at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Quebec's designee pursuant to its investor rights agreement with the Company.

10:00 EDT Cinemark rises 6.5% - Cinemark is up 6.5%, or $1.22 to $19.98.

10:00 EDT PlayAGS rises 9.1% - PlayAGS is up 9.1%, or 77c to $9.25.

10:00 EDT Mytheresa falls -7.4% - Mytheresa is down -7.4%, or -27c to $3.40.

09:47 EDT Gatos Silver falls -5.5% - Gatos Silver is down -5.5%, or -50c to $8.59.

09:47 EDT McEwen Mining falls -9.2% - McEwen Mining is down -9.2%, or -$1.01 to $9.94.

09:47 EDT Torrid rises 7.4% - Torrid is up 7.4%, or 34c to $4.94.

09:45 EDT Procter & Gamble recalls 8.2M defective bags of Tide, Gain, Ace, Ariel Pods - Procter & Gamble announced a voluntary packaging recall of Tide Pods, Gain Flings, Ace Pods and Ariel Pods liquid laundry detergent packets packaged in flexible film bags. This recall announcement applies only to bags distributed in the United States. The outer packaging meant to prevent access to the contents can split open near the zipper track, posing a risk of serious injury to children and other vulnerable populations if the contents of the laundry detergent packets are ingested, as well as posing a risk of skin or eye injuries. Ingestion of a large quantity of any surfactant-containing household cleaning products can cause death among individuals with underlying health issues.

09:40 EDT GCT Semiconductor Holding Inc trading resumes

09:35 EDT GCT Semiconductor Holding Inc trading halted, volatility trading pause

09:22 EDT Honeywell Safety Products issues voluntary recall of eyewash cartridges - Honeywell Safety Products USA, Inc. is voluntarily recalling Fendall 2000 Non-Sterile Eyewash Cartridge for the Fendall 2000 Eyewash Station. This recall is being conducted at the industrial consumer level. Honeywell's supplier of the Fendall 2000 Non-Sterile Eyewash Cartridge has been found to be non-compliant with current good manufacturing practice requirements. Use of or exposure to the eyewash without seeking medical attention afterwards could result in a range of ocular infections such bacterial keratitis or endophthalmitis. Immunocompromised individuals, those sustaining ocular injuries that damage the corneal epithelium, and those sustaining penetrating ocular injuries are at higher risk of potential infection. To date, Honeywell Safety Products USA, Inc. has not received any reports of adverse events related to this recall. Reference Link

09:08 EDT Bristol Myers, 2seventy Bio's Abecma approved by U.S. FDA - Bristol Myers Squibb (BMY) and 2seventy bio (TSVT) have announced that on April 4, 2024, the U.S. Food and Drug Administration, FDA, approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial. This approval expands Abecma's indication, making it available in earlier lines to patients who have relapsed or become refractory after exposure to these three main classes of treatment, after two prior lines of therapy. Abecma is administered as a one-time infusion, with a new recommended dose range of 300 to 510 x 106 CAR-positive T cells. "We are extremely pleased that Abecma will be available to many more patients in the U.S.," said Chip Baird, chief executive officer, 2seventy bio. "This approval represents another important milestone for patients, for Abecma, and for 2seventy bio as we remain committed to increasing treatment options and working to improve outcomes for patients living with multiple myeloma."

09:04 EDT Sanara MedTech appoints Jake Waldrop as COO - Sanara MedTech (SMTI) announced the appointments of Jake Waldrop as COO and Tyler Palmer as Chief Corporate Development and Strategy Officer. Most recently Mr. Waldrop held the position of CFO for Trilliant Surgical, and after their sale to Enovis in early 2021, Jake held the position of Vice President of Finance and Integrations for the newly founded Foot and Ankle division of Enovis (ENOV). On his most recent role, Mr. Palmer served as the Senior Vice President of Corporate Development, Strategy, and Product at AQuity Solutions. Mr. Waldrop's appointment is effective April 15, 2024 and Mr. Palmer's appointment was effective April 1, 2024.

09:02 EDT Edgio receives expected notice from NASDAQ - Edgio announced that it received an expected notice on April 4, 2024 from The Nasdaq Stock Market, Nasdaq, stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market.

09:01 EDT Cushman & Wakefield selected by MIT for generative AI - Cushman & Wakefield announced that the commercial real estate services firm will participate in the MIT Working Group on Generative AI and the Work of the Future. This initiative, led by the Massachusetts Institute of Technology, aims to explore the implications of generative AI on the future of work. "As a company committed to innovation and advancing our industry, we recognize the importance of understanding and harnessing the potential of generative AI," said Sal Companieh, Chief Digital & Information Officer. "Joining forces with MIT and other leading organizations in this working group allows us to contribute to the conversation while gaining valuable insights that will shape the future of our workforce."

09:01 EDT Softchoice announces new strategic partnership agreement with Microsoft - Softchoice Corporation (SFTCF) announced that it has signed a new strategic partnership framework agreement with Microsoft Corporation (MSFT) to further enhance its capabilities and capacity to develop, sell, and deliver Microsoft's cloud and digital workplace AI and security solutions, including Microsoft Copilot for Microsoft 365 and Microsoft Copilot for Security. Earlier in 2024, Softchoice launched its AI Solutions team, which delivers next-generation cloud and workplace AI offerings for organizations across the US and Canada.

08:46 EDT IBM, the government of Spain collaborate on AI strategy - The President of the Government, Pedro Sanchez, and the Senior Vice President of IBM and Director of IBM Research, Dario Gil, met this afternoon at the Moncloa Complex, where they celebrated the new agreement reached between the Executive and IBM that will allow the development of foundational models for Artificial Intelligence, native in Spanish and co-official languages. During the meeting, which was also attended by the Minister for Digital Transformation and the Civil Service, Jose Luis Escriva; the director of the Office of Economic Affairs of the Presidency of the Government, Manuel de la Rocha, and the president of IBM Spain, Portugal, Greece and Israel, Horacio Morell, they shared challenges and initiatives that are opening up in the field of artificial intelligence and supercomputing. Afterwards, the Government of Spain, through its Ministry for Digital Transformation, the Civil Service, and IBM today signed a Memorandum of Understanding to promote their collaboration in the field of Artificial Intelligence and AI supercomputing, advance the development and practical deployment of open, ethical and responsible generative AI in Spain, and sharing the vision to create a leading suite of foundation models including both large language models and small language models, proficient in the Spanish language and co-official languages. During the meeting at La Moncloa, the President stressed that agreements such as this one demonstrate Spain's commitment to accelerate the ethical and responsible use of AI, particularly in the public sector, with great impact on productivity for many sectors of the economy and on Europe's strategic autonomy.

08:33 EDT IO Biotech appoints Faical Miyara as CBO - IO Biotech announced that Faical Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. Most recently, he served as Vice President, Head of Business Development Oncology, then Head of External Innovation Oncology, Lead on Venture Capital Activities at Ipsen Biosciences.

08:21 EDT Twin Vee appoints Michael Dickerson as chief financial, administrative officer - Twin Vee PowerCats announced the appointment of Michael Dickerson as its Chief Financial & Administrative Officer, effective April 4, 2024. Mr. Dickerson succeeds former CFO Carrie Gunnerson, who was appointed in October 2021. He most recently served in a consulting capacity at Savannah River Logistics as their Executive Vice President, Chief Financial & Administrative Officer, and Treasurer.

08:17 EDT Baker Hughes awarded order for electric-driven liquefaction technologies - Baker Hughes was awarded an order from Black & Veatch to supply Cedar LNG in Canada with electric driven liquefaction technologies. The award was booked in the first quarter of 2024. Baker Hughes will supply a range of turbomachinery equipment, including four electric-driven main refrigeration compressors, two electric-driven boil-off gas compressors and six centrifugal pumps. Powered by renewable electricity, Cedar LNG will be one of the lowest carbon intensity LNG facilities in the world.

08:16 EDT Immunome to presents preclinical data for IM-3050 at AACR - Immunome announced that it will present preclinical data for IM-3050, the company's lead lutetium-177 radioligand therapy targeting fibroblast activation protein. Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research, AACR, Annual Meeting 2024, which is taking place April 5-10 in San Diego, California. "FAP is an attractive target for cancer therapy, but trials with first-generation FAP-RLTs have produced modest clinical responses, indicating the need for novel agents with improved therapeutic properties," commented Dr. Higgins. "We believe IM-3050 has best-in-class potential and look forward to sharing preclinical data for the program at AACR." Immunome expects to submit an Investigational New Drug application to the U.S. Food & Drug Administration for IM-3050 in the first quarter of 2025.

08:15 EDT L3Harris Technologies announces agreement to sell non-core assets for $200M - L3Harris Technologies has signed a definitive agreement under which an affiliate of Kanders & Company will acquire its antenna and related businesses for $200 million. The transaction is expected to close this quarter and is subject to customary closing conditions and regulatory approvals. The agreement aligns with L3Harris' portfolio-shaping strategy for non-core assets, with transaction proceeds to be used consistent with capital allocation plans. The transaction is made up of $175 million of cash at closing and a $25 million seller note. The businesses L3Harris will divest offer a variety of airborne and ground-based antennas and test equipment. They are part of the Space & Airborne Systems segment and employ approximately 375 people.

08:12 EDT DZS receives delinquency notification letter from Nasdaq Stock Market - DZS announced that on April 1, 2024, as expected, it received a delinquency notification letter from the Nasdaq Stock Market indicating that DZS is not in compliance with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1) because DZS did not timely file its Annual Report on Form 10-K for the year ended December 31, 2023. The notification letter has no immediate effect on the listing or trading of DZS common stock on the Nasdaq Capital Market. As previously reported by DZS in its Notification of Late Filing on Form 12b-25, filed with the Securities and Exchange Commission on March 18, 2024, DZS was unable to timely file the Form 10-K without unreasonable effort or expense by the prescribed due date for such filing. As previously disclosed, following failure to file its Quarterly Report on Form 10-Q for the three months ended June 30, 2023 and September 30, 2023, DZS received a Staff Delisting Determination from the Nasdaq Listing Qualifications Department indicating that, as a result of DZS's delay in filing the Delinquent Quarterly Reports, it is not in compliance with the Rule. DZS requested a hearing regarding the Staff Determination before a Nasdaq Hearings Panel and was granted a further stay of any suspension or delisting action pending the hearing process, in accordance with the procedures set forth in the Staff Determination. As of the date of this release, DZS has not yet appeared before the Panel to appeal the determination by the Nasdaq Listing Qualifications Department and to seek an additional extension of the stay of any suspension or delisting action until August 3, 2024, the latest extension date that the Panel has the discretion to grant DZS.

08:08 EDT H&R Block, Domino's Pizza partner to incentivize last-minute tax filers - H&R Block (HRB) is helping last-minute filers lower their stress level and experience the joy of completing an important task five days ahead of the filing deadline. New clients who file in-person or virtually with an H&R Block tax pro by April 10th will receive $10 in free food at Domino's (DPZ).

08:05 EDT Protara announces alignment with FDA on path forward for IV Choline Chloride - Protara Therapeutics has reached alignment with the U.S. Food and Drug Administration on a registrational path forward for intravenous Choline Chloride, an investigational phospholipid substrate replacement. The Company had previously been pursuing an indication in intestinal failure-associated liver disease and following feedback from FDA, will now pursue a broader indication in patients on parenteral nutrition who are or may become unable to synthesize choline from oral or enteral nutrition sources. The Company plans to advance the development of IV Choline Chloride as a source of choline for adult and adolescent patients on long-term PN. The FDA has granted IV Choline Chloride Orphan Drug Designation for the prevention of choline deficiency in PN patients. Choline is recommended for patients on PN by the American Society for Parenteral and Enteral Nutrition Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-Trace Element Products, as well as by the European Society for Clinical Nutrition and Metabolism in their Guideline on Home Parenteral Nutrition. The FDA indicated that a single study with an endpoint of restoring choline levels in PN patients could serve as the basis for a regulatory filing for IV Choline Chloride. Based on this feedback, the Company intends to assess the safety and efficacy of IV Choline Chloride in its planned seamless Phase 2b/3 double-blinded, randomized, placebo-controlled THRIVE-3 study in adolescents and adults on long-term PN when oral or enteral nutrition is not possible, insufficient, or contraindicated. The Phase 2b portion of the study, which will seek to establish the pharmacokinetics profile of IV Choline Chloride, will enroll approximately 24 patients who will receive one of three daily doses of IV Choline Chloride for 24 weeks. During the randomized, double-blind Phase 3 portion of the study, approximately 100 patients will receive either high dose IV Choline Chloride, low dose Choline Chloride, or placebo for 24 weeks. The primary endpoint of this portion of the study will seek to demonstrate IV Choline Chloride as a durable source of choline. Secondary endpoints will assess the impact of choline replacement on liver function. All patients will be eligible to enter an open-label extension. The Company intends to initiate this study in the first half of 2025. In previous studies, treatment with IV Choline Chloride successfully increased plasma choline concentrations in patients on PN and was also shown to improve steatosis, a key marker of liver injury.

08:03 EDT Akoya Biosciences showcases spatial biology 2.0 solutions at AACR meeting - Akoya Biosciences will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoya's platforms. Industry-leading capabilities of the company's spatial biology platforms will be presented during Akoya's Spotlight Theater, titled "Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unprecedented Scale" on Monday, April 8 at 3 PM. The event will describe how researchers are revealing new insights into the tumor microenvironment, elucidating the mechanisms of cancer treatment response, and paving the way for spatial biology to impact patient outcomes. Deployment of Akoya's PhenoCycler-Fusion 2.0, PhenoImager HT 2.0, and PhenoCode Panels across the research continuum, from ultrahigh-plex discoveries to actionable signatures, will be described by the presenters: Suzanne K. Coberly, MS MD, FCAP, Scientific Senior Director, Discovery & Translational Pathology, Oncogenesis TRC, Bristol Myers Squibb; Arutha Kulasinghe PhD, Scientific Director of the Queensland Spatial Biology Center in Brisbane, Group Leader at The University of Queensland; Pascal Bamford, PhD, Senior Vice President, R&D and Laboratory Operations, Akoya Biosciences. Dr. Kulasinghe will also present a talk entitled "Ultra high-plex profiling of the tumor microenvironment" on April 6 from 12:36 PM - 12:54 PM PT in Session MW14 - Choosing and Using Antibodies for Spatial Informed Protein Expression. He will discuss the development of ultrahigh-plex antibody panels for the comprehensive characterization of the tumor microenvironment. Akoya Biosciences will demonstrate new uses of its PhenoCode Signature Panels for accelerating discovery and validation of spatial biomarkers using the PhenoImager HT 2.0 platform. The company will also present initial findings from the Thermo Fisher Scientific ViewRNA assays on the PhenoCycler-Fusion 2.0. PhenoCycler-Fusion 2.0: Offers automated multi-slide capabilities, allowing researchers to efficiently generate ultrahigh-plex, multiomic spatial phenotyping data for larger samples at exceptional speeds. PhenoImager HT 2.0: Features targeted PhenoCode Signature Panels and onboard spectral unmixing, simplifying biomarker development and validation workflows for large scale studies.

08:01 EDT Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - Taysha Gene Therapies announced that, on April 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 140,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $2.84 per share, which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

07:40 EDT Alta Global debuts with launch of IPO on NYSE - Alta Global Group announces that its initial public offering on the NYSE American exchange under the ticker symbol 'MMA' was a strategic move that was a natural progression for the company's leadership and enhanced vision for the combat sports industry. With a mission to empower community driven growth in the global martial arts and combat sports sector, Alta leverages cutting-edge technology to bridge the gap between passion and participation. Under the stewardship of Alta Global Group Founder and CEO, Nick Langton, the company has evolved from working with MMA gyms and world class fighters to grow into a technology company dedicated to uniting passion and participation in global combat sports through multiple digital platforms. Alta's comprehensive platform integrates four core products, including the Alta Warrior Training Program, UFC Fight Fit Program, Alta Academy and Alta In-Gym Training, strategically positioned to capitalize on the industry's growth, with over 45,597 martial arts and combat sports gyms in the US alone according to IBISWorld statistics.

07:34 EDT Kura Oncology reports inducement grants under Nasdaq listing rule - Kura Oncology announced that on April 1, 2024, the Compensation Committee of the Company's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase 49,500 shares of common stock to four new employees under the Company's 2023 Inducement Option Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $21.82 per share, the Company's closing sales price on April 1, 2024, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2023 Inducement Option Plan and the terms and conditions of an applicable stock option agreement covering the grant.

07:31 EDT Ancora issues letter to shareholder on Norfolk Southern COO Orr - Ancora Holdings Group, which owns a large equity stake in Norfolk Southern Corporation, issued the below letter to fellow shareholders regarding the Board of Directors' apparent failures of diligence and poor judgment in appointing John Orr as COO. "Unfortunately, the Board and CEO Alan Shaw continue to take actions that place their self-preservation ahead of our shared goal. The most recent example of this is their decision to enter into a costly and opaque agreement to extricate John Orr from Canadian Pacific Kansas City Limited and make him the third COO in two and a half years under Mr. Shaw... Here are just a few of the key points you need to know about this latest failure of governance: The Board's reactive process for hiring a COO was run from a position of weakness and did not even include a discussion with our proposed candidate... Based on Norfolk Southern's own disclosures and statements regarding the importance of the Meridian Speedway and Terminal, we estimate the undisclosed consideration paid by the Company to hire Mr. Orr... The Board and Mr. Shaw have failed to disclose all of the relevant details about Norfolk Southern's agreement with CPKC... The Board did not aggressively search for or hire a COO with important experience at an Eastern Class I railroad, but rather one of convenience with ties to current director Claude Mongeau... The Board did not hire a COO with expertise in Precision Scheduled Railroading implementations; Orr has been accused of abusive behavior and serious misconduct in the workplace... Concerns about Mr. Orr's workplace behavior at Canadian National Railway Compan should have been known to the Board based on our private warning... The only industry endorsements for Mr. Orr since his appointment as COO have come from Mr. Mongeau and individuals at CPK.

07:03 EDT Novocure announces 20 presentations at AACR 2024 - Novocur announced 20 presentations on Tumor Treating Fields therapy will be delivered at the American Association for Cancer Research, AACR, Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, include new insights on how TTFields therapy can potentially enhance the immune system's ability to combat cancer cells and on TTFields therapy's effects and mechanisms in pancreatic cancer. "The research we and our collaborators are presenting at the AACR Annual Meeting underscores the potential of Tumor Treating Fields therapy in treating various solid tumor types," said Moshe Giladi, Ph.D., Novocure's Chief Science Officer. "We continually explore the science of TTFields therapy to improve our product and make a difference in the lives of patients with cancer, and we are eager to discuss some of our latest insights with leading cancer investigators."

07:03 EDT AstraZeneca releases ADRIATIC Phase III trial results on IMFINZI - Results of the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy compared to placebo after cCRT. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "These exciting results build on the transformative efficacy of IMFINZI in extensive-stage small cell lung cancer and demonstrate the potential to bring a curative-intent immunotherapy treatment to this earlier-stage setting of small cell lung cancer for the first time. These data, together with the PACIFIC data in unresectable, Stage III non-small cell lung cancer, underscore the pioneering role of IMFINZI in the treatment of early lung cancer following chemoradiotherapy."

07:02 EDT Upbound Group appoints Langenstein as new independent director - Upbound Group announced that, effective April 1, 2024, Molly Langenstein has been appointed to the Upbound Board of Directors as a new independent director. Most recently, Langenstein served as the Chief Executive Officer and President and a member of the board of directors of Chico's FAS

07:01 EDT Natera announces surveillance analysis from IMvigor011 study - Natera announced an analysis from the IMvigor011 study that was presented at the European Association of Urology Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer patients who tested serially negative with Signater, Natera's personalized and tumor-informed molecular residual disease test. The analysis presented at the EAU Congress evaluated clinical outcomes in 171 high-risk MIBC patients who entered screening for IMvigor011 and remained MRD-negative during the surveillance window. Key takeaways from the presentation include: Overall survival rates of 100% at 12 months and 98% at 18 months, in patients who remained serially MRD-negative. Disease-free survival rates of 92% at 12 months and 88% at 18 months, in patients who remained serially MRD-negative. Concludes that patients who remain MRD-negative on serial testing may be spared from adjuvant treatment.

06:52 EDT Becton Dickinson announes commercial release of cell sorters - BD announced the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments. The new BD FACSDiscover S8 Cell Sorters feature BD CellView Image Technology, profiled on the cover of the journal Science in 2022, and BD SpectralFX Technology - bringing to market breakthrough innovations in real-time imaging and spectral flow cytometry. The three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family complement the five-laser instrument launched last year and provide scientists greater access, options, and flexibility to incorporate real-time imaging and spectral cell sorting technology in their labs.

06:38 EDT Johnson & Johnson: ShockWave Medical deal to accelerate revenue growth - The acquisition of Shockwave (SWAV) accelerates Johnson & Johnson MedTech's ongoing efforts to increase its presence in high-growth markets with unmet need, while expanding its reach and scale globally. The proposed transaction adds a high-performing business in an underpenetrated category with a strong pipeline and an attractive growth and margin profile. The transaction is expected to accelerate revenue growth for both Johnson & Johnson (JNJ)and Johnson & Johnson MedTech. Shockwave is ultimately expected to become Johnson & Johnson MedTech's thirteenth priority platform, as defined by annual sales of at least $1B.

06:33 EDT Teleios Capital Partners supports JBT's current proposal for Marel - Teleios Capital Partners, a long-standing shareholder in Marel, issued a statement. Attributed to Adam Epstein, Co-Founder of Teleios Capital Partners: "As a long-term shareholder for over five years, we wrote to Marel last November to convey our support for rebuffing JBT's initial approach, which we felt sought to capitalise on Marel's governance shortcomings. We welcome JBT's decision to revise its position, through both an improved valuation and more compelling deal structure, which we believe is to the benefit of all shareholders, including those who wish to participate in the combined company's upside. We support their current proposal."

06:31 EDT Teradata names Richard Petley as Chief Revenue Officer - Teradata announced the appointment of Richard Petley as Chief Revenue Officer, effective immediately. Petley was previously Teradata's EVP, Global Sales, and he succeeds Todd Cione, who is leaving the company to pursue another professional opportunity.

05:57 EDT JBT Corp., Marel execute definitive transaction agreement - JBT Corporation announced that JBT and Marel have executed a definitive transaction agreement related to JBT's previously announced intention to make a voluntary takeover offer for all of the issued and outstanding shares of Marel. The transaction agreement includes the terms of the offer and other important governance, social, and operating items relating to the proposed business combination of JBT and Marel. The transaction agreement was approved by the Boards of Directors of both companies. JBT and Marel are continuing to work expeditiously to finalize and submit a preliminary proxy statement/prospectus on Form S-4 with the U.S. SEC as well as an offer document and prospectus with the Icelandic Financial Supervisory Authority of the Central Bank of Iceland, as required to launch the offer. Pending final approval by the FSA, JBT currently expects to launch the offer in May 2024. The transaction is expected to close by the end of 2024, subject to regulatory clearance and applicable shareholder approvals. The economic terms of the offer are consistent with JBT's prior announcement on January 19, 2024. Subject to a proration feature, Marel shareholders will have the option to elect to receive either all cash, all JBT common stock, or a combination of cash and JBT common stock in respect of each Marel share as outlined below: All cash: EUR 3.60 in cash. All JBT common stock: 0.0407 JBT shares. Combination of cash and JBT common stock: EUR 1.26 in cash and 0.0265 JBT shares. The economic terms above utilize a reference share price of $96.25 per share of JBT. Based on both the proration feature and the agreed upon JBT reference share price, the estimated consideration mix will be 65 percent stock and 35 percent cash. This will result in Marel shareholders receiving, in the aggregate, EUR 950M in cash and holding approximately a 38 percent ownership interest in the combined company. JBT intends that the combined company will remain listed on the New York Stock Exchange and will submit a secondary listing application to list a portion of JBT's common stock on Nasdaq Iceland. Marel shareholders will have the ability to elect to receive JBT shares listed either on the NYSE or, upon a successful application by JBT for a listing on Nasdaq Iceland, on Nasdaq Iceland. Eyrir Invest hf., the largest shareholder in Marel with approximately 25 percent of Marel's issued and outstanding ordinary shares, has irrevocably undertaken to JBT to accept the offer in respect of all of its shares in Marel.

05:54 EDT Nutex Health announces 1-for-15 reverse stock split - Nutex Health announced a 1-for-15 reverse stock split of its common stock effective with the market opening on Tuesday April 10. The reverse stock split will take legal effect at 11:59pm Eastern Time on April 9, and the company's common stock will open for trading on The Nasdaq Capital Market on April 10 on a post-split basis, under the existing ticker symbol "NUTX" but with new CUSIP number 67079U207. The reverse stock split is part of the company's plan to regain compliance with the minimum bid price requirement for the continued listing on The Nasdaq Capital Market.

05:53 EDT AT&T commitment to help close digital divide increases to $5B - AT&T plans to invest an additional $3B by 2030 to help close the US digital divide, after initially committing $2B by 2024, which helped nearly 5M Americans, the company announced Thursday. "Connectivity is critical for success and prosperity in America today. Whether it's a first-generation high school graduate applying for college, a veteran accessing telehealth services, or a grandparent connecting with their family thousands of miles away -- we want to help unlock greater possibility for the millions of people who remain unconnected," said AT&T CEO John Stankey. "The pace of innovation and the global economy aren't waiting on anyone, and we're committed to bringing connectivity and digital literacy in reach for all Americans."